Insider · CIK 0001449008

Waksal Harlan

Reports to the SEC for 4 companies · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001449008

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-07-20	FRNMFreenome, Inc.C Conversion	Former Director	CConversion	+30K sh	—	—	30,000
2026-07-20	FRNMFreenome, Inc. · Class B Ordinary SharesC Conversion	Former Director	CConversion	−30K sh	—	—	0
2024-12-09	LYRALyra Therapeutics, Inc. · Performance-based Restricted Stock UnitsA Award	Director, Executive Chair	AAward	−128K sh	—	—	0
2024-03-18	LYRALyra Therapeutics, Inc.A Award	Director, Executive Chair	AAward	+275K sh	—	—	536,966
2023-11-10	LYRALyra Therapeutics, Inc.P Purchase	Director, Executive Chair	PPurchase	+25K sh	$2.96	+$74.1K	261,966
2023-01-31	LYRALyra Therapeutics, Inc. · Stock OptionA Award	Director, Executive Chair	AAward	+200K sh	—	—	200,000
2022-06-16	LYRALyra Therapeutics, Inc. · Stock OptionA Award	Director, Executive Chair	AAward	+953K sh	—	—	953,002
2022-04-12	LYRALyra Therapeutics, Inc.P Purchase	Director, Executive Chair	PPurchase	+237K sh	$4.22	+$1M	236,966
2022-02-16	LYRALyra Therapeutics, Inc. · Stock OptionA Award	Director, Executive Chair	AAward	+520K sh	—	—	520,000
2021-11-09	Kadmon Holdings, Inc.D Disposition to Issuer	Director, President, CEO	DDisposition to Issuer	−178K sh	$9.50	−$1.69M	0
2021-11-09	Kadmon Holdings, Inc.Stock Appreciation RightD Disposition to Issuer	Director, President, CEO	DDisposition to Issuer	+655K sh	$5.86	+$3.84M	0
2021-11-09	Kadmon Holdings, Inc.Performance Stock Option(right to buy)D Disposition to Issuer	Director, President, CEO	DDisposition to Issuer	+983K sh	$5.44	+$5.34M	0
2021-11-09	Kadmon Holdings, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, President, CEO	DDisposition to Issuer	+1.35M sh	$5.35	+$7.22M	0
2021-11-09	Kadmon Holdings, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, President, CEO	DDisposition to Issuer	+2M sh	$5.54	+$11.1M	0
2021-11-09	Kadmon Holdings, Inc.Equity Appreciation Rights UnitD Disposition to Issuer	Director, President, CEO	DDisposition to Issuer	+750 sh	$3.50	+$2,625	0
2021-05-13	Kadmon Holdings, Inc.A Award	Director, President, CEO	AAward	+25K sh	$3.56	+$89K	177,945
2021-04-03	Kadmon Holdings, Inc.Performance Stock Option (right to buy)A Award	Director, President, CEO	AAward	+327K sh	—	—	982,500
2021-01-08	Kadmon Holdings, Inc.Stock Option (right to buy)A Award	Director, President, CEO	AAward	+2M sh	—	—	2,000,000
2020-09-10	Kadmon Holdings, Inc.Performance Stock Option (right to buy)A Award	Director, President, CEO	AAward	+109K sh	—	—	655,002
2020-03-13	Kadmon Holdings, Inc.P Purchase	Director, President, CEO	PPurchase	+16K sh	$2.93	+$46.8K	152,945
2020-03-11	Kadmon Holdings, Inc.P Purchase	Director, President, CEO	PPurchase	+12.6K sh	$3.96	+$49.9K	136,945
2019-11-19	Kadmon Holdings, Inc.Stock Option (right to buy)A Award	Director, President, CEO	AAward	+1.35M sh	—	—	1,350,000
2019-11-19	Kadmon Holdings, Inc.Stock Option (right to buy)A Award	Director, President, CEO	AAward	+1.35M sh	—	—	1,350,000
2019-10-24	Kadmon Holdings, Inc.Performance Stock Option (right to buy)A Award	Director, President, CEO	AAward	+109K sh	—	—	545,835
2019-09-10	Kadmon Holdings, Inc.Performance Stock Option (right to buy)A Award	Director, President, CEO	AAward	+109K sh	—	—	436,668
2019-06-14	Kadmon Holdings, Inc.Performance Stock Option (right to buy)A Award	Director, President, CEO	AAward	+109K sh	—	—	327,501
2019-04-03	Kadmon Holdings, Inc.Performance Stock Option (right to buy)A Award	Director, President, CEO	AAward	+218K sh	—	—	218,334
2019-03-29	Kadmon Holdings, Inc.A Award	Director, President, CEO	AAward	+7,716 sh	$2.25	+$17.4K	124,345
2018-09-28	Kadmon Holdings, Inc.A Award	Director, President, CEO	AAward	+5,882 sh	$2.84	+$16.7K	116,629
2017-12-08	Kadmon Holdings, Inc.Stock Appreciation RightA Award	Director, President, CEO	AAward	+655K sh	—	—	655,000
2017-08-10	Kadmon Holdings, Inc.P Purchase	Director, President, CEO	PPurchase	+5,000 sh	$2.27	+$11.3K	110,747
2017-08-08	Kadmon Holdings, Inc.P Purchase	Director, President, CEO	PPurchase	+3,707 sh	$2.34	+$8,666.595	105,747
2016-11-16	Kadmon Holdings, Inc.P Purchase	Director, President, CEO	PPurchase	+2,000 sh	$6.37	+$12.7K	102,040
2016-11-14	Kadmon Holdings, Inc.P Purchase	Director, President, CEO	PPurchase	+2,000 sh	$6.79	+$13.6K	100,040
2015-11-19	ELOXEloxx Pharmaceuticals, Inc. · Company Stock OptionA Award	Director	AAward	+40K sh	$0.25	+$10K	40,000
2015-05-18	ELOXEloxx Pharmaceuticals, Inc. · Common Stock OptionA Award	Director	AAward	+11.3K sh	$0.97	+$11K	147,693
2015-02-19	ELOXEloxx Pharmaceuticals, Inc. · Common Stock OptionA Award	Director	AAward	+26.6K sh	$0.54	+$14.3K	136,353
2014-11-18	ELOXEloxx Pharmaceuticals, Inc. · Common Stock Option (right to buy)A Award	Director	AAward	+38K sh	—	—	92,332
2014-11-18	ELOXEloxx Pharmaceuticals, Inc. · Common Stock Option (right to buy)A Award	Director	AAward	+17.2K sh	$0.42	+$7,210.56	109,500
2013-09-13	ELOXEloxx Pharmaceuticals, Inc. · Common Stock OptionA Award	Director	AAward	+530K sh	—	—	3,236,572
2013-09-13	ELOXEloxx Pharmaceuticals, Inc. · Common Stock OptionA Award	Director	AAward	+530K sh	—	—	3,236,572
2013-05-17	ELOXEloxx Pharmaceuticals, Inc. · Common Stock OptionA Award	Director	AAward	+273K sh	—	—	2,716,572
2013-02-19	ELOXEloxx Pharmaceuticals, Inc. · Common Stock OptionA Award	Director	AAward	+146K sh	—	—	2,433,316
2012-11-16	ELOXEloxx Pharmaceuticals, Inc. · Common Stock OptionsA Award	Director	AAward	+420K sh	—	—	2,122,330
2012-11-16	ELOXEloxx Pharmaceuticals, Inc. · Common Stock OptionsA Award	Director	AAward	+165K sh	—	—	2,287,482
2012-08-08	ELOXEloxx Pharmaceuticals, Inc.C Conversion	Director	CConversion	+859K sh	$0.26	+$223K	2,805,750
2012-08-08	ELOXEloxx Pharmaceuticals, Inc. · Series B Convertible Preferred StockC Conversion	Director	CConversion	−200 sh	—	—	0
2012-05-16	ELOXEloxx Pharmaceuticals, Inc. · Common Stock OptionA Award	Director	AAward	+46.3K sh	—	—	1,702,330
2012-02-16	ELOXEloxx Pharmaceuticals, Inc. · Common Stock OptionA Award	Director	AAward	+45.8K sh	—	—	1,655,988
2012-01-06	ELOXEloxx Pharmaceuticals, Inc.P Purchase	Director	PPurchase	+962K sh	$0.26	+$250K	1,902,590

Recent filings

Accepted (ET)
Jul 294
Waksal Harlan0001449008-26-000004
SEC(opens sec.gov)
Dec 114
Waksal Harlan0000950170-24-135515
SEC(opens sec.gov)
Mar 204
Waksal Harlan0000950170-24-034350
SEC(opens sec.gov)
Nov 134
Waksal Harlan0000950170-23-063137
SEC(opens sec.gov)
Feb 24
Waksal Harlan0000899243-23-003522
SEC(opens sec.gov)
Jun 214
Waksal Harlan0000899243-22-023336
SEC(opens sec.gov)
Apr 134
Waksal Harlan0000899243-22-014737
SEC(opens sec.gov)
Feb 184
Waksal Harlan0000899243-22-007038
SEC(opens sec.gov)
Nov 94
Waksal Harlan0001104659-21-136412
SEC(opens sec.gov)
May 174
Waksal Harlan0001593968-21-001330
SEC(opens sec.gov)
Apr 64
Waksal Harlan0001593968-21-001092
SEC(opens sec.gov)
Jan 124
Waksal Harlan0001593968-21-000120
SEC(opens sec.gov)
Sep 104
Waksal Harlan0001593968-20-001855
SEC(opens sec.gov)
Mar 164
Waksal Harlan0001593968-20-000776
SEC(opens sec.gov)

Companies

Address

C/O PERCEPTIVE CAPITAL SOLUTIONS HOLDING 51 ASTOR PLACE, 10TH FLOOR

NEW YORK, NY, 10003